New approaches to the modulation of cyclooxygenase-2 and 5-lipoxyenase pathways

Current Topics in Medicinal Chemistry

Volumn 7, Issue 3, 2007, Pages 297-309

  Gonzalez Periz A ^a   Claria J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

5S hydroperoxyeicosatetraenoic acid; Cancer cell; Inflammation; Peroxisome proliferator activated receptors (PPARs); Thromboxane (TX)

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPENTENONE DERIVATIVE; IBUPROFEN; ICOSANOID; INDOMETACIN; KETOPROFEN; LICOFELONE; LIPOXIN; LIPOXYGENASE INHIBITOR; N [5 (4 FLUOROPHENOXY) 2 THIENYL]METHANESULFONAMIDE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; PIROXICAM; PLACEBO; PROSTAGLANDIN DERIVATIVE; ROFECOXIB; SULINDAC; TEPOXALIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADENOMATOUS POLYP; ANTINEOPLASTIC ACTIVITY; CANCER; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TISSUE LEVEL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME LOCALIZATION; GASTROINTESTINAL TOXICITY; GENETIC CODE; HEART INFARCTION; HUMAN; INFLAMMATORY DISEASE; LIPOGENESIS; LIVER TOXICITY; NONHUMAN; OSTEOARTHRITIS; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS;

ANTI-INFLAMMATORY AGENTS; ARACHIDONATE 5-LIPOXYGENASE; ARACHIDONIC ACID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG DESIGN; HUMANS; LIPOXYGENASE INHIBITORS; METABOLIC NETWORKS AND PATHWAYS; NEOPLASMS;

EID: 33847638036     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607779941378     Document Type: Review

References (180)

1. Ohki, S.; Ogino, N.; Yamamoto, S.; Hayaishi, O. Prostaglandin hydroperoxidase, an integral part of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J. Biol. Chem. 1979, 254, 829-836.
2. Smith, W. L.; Song, I. The enzymology. of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat. 2002, 68-69, 115-118.
3. Dudzinski, D. M.; Serhan, C. N. Pharmacology of eicosanoids. In Principles of pharmacology: The pathophysiologic basis Of drug therapy; Golan, D. E.; Tashjian, A. H.; Armstrong, E. J.; Galanter, J. M.; Armstrong, A. W.; Arnaout, R. A.; Rose, H. S.; Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, 2004; pp 627-646.
4. Jakobsson, P. J.; Thoren, S.; Morgenstern, R.; Samuelsson, B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc. Natl. Acad. Sci. USA 1999, 96, 7220-7225.
5. 2 biosynthesis. J. Biol. Chem. 2000, 275, 32775-32782.
6. Murakami, M.; Kudo, I. Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog. Lipid Res. 2004, 43, 3-35.
7. Tanikawa, N.; Ohmiya, Y.; Ohkubo, H.; Hashimoto, K.; Kangawa, K.; Kojima, M.; Ito, S.; Watanabe, K. Identification and characterization of a novel type of membrane-associated prostaglandin E synthase. Biochem. Biophys. Res. Commun. 2002, 291, 884-889.
8. Mancini, J. A.; Blood, K.; Gruay, J.; Gordon, R.; Claveau, D.; Chan, C. C.; Riendeau, D. Cloning, expression, and up-regulation of inducible rat prostaglandin E synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis. J. Biol. Chem. 2001, 276, 4469-4475.
9. Breyer, R. M.; Bagdassarian, C. K.; Myers, S. A.; Breyer, M. D. Prostanoid receptors: subtypes and signaling. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 661-690.
10. Evans, R. M.; Barish, G. D.; Wang, Y. X. PPARs and the complex journey to obesity. Nat. Med. 2004, 10, 355-361.
11. Kujubu, D. A.; Fletcher, B. S.; Vamum, B. C.; Lim, R. W.; Herschman, H. R. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J. Biol. Chem. 1991, 266, 12866-12872.
12. Yie, W.; Chipman, J. G.; Robertson, D. L.; Erikson, R. L.; Simmons, D. L. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl. Acad Sci. USA 1991, 88, 2692-2696.
13. O'Banion, M. K.; Sadowski, H. B.; Winn, V.; Young, D. A. A serum-and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol. Chem. 1991, 266, 23261-23267.
14. Jones, D. A.; Carlton, D. P.; McIntyre, T. M.; Zimmerman, G. A.; Prescott, S. M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol. Chem. 1993, 268, 9049-9054.
15. Tanabe, T.; Tohnai, N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat. 2002, 68-69, 95-114.
16. Hla, T.; Neilson, K. Human cyclooxygenase-2 cDNA. Proc. Natl. Acad. Sci. USA 1992, 89, 7384-7388.
17. Clària, J. Cyclooxygenase-2 biology. Curr. Pharm. Des. 2003, 9, 2177-2190.
18. Herschman, H. R. Prostaglandin synthase 2. Biochim. Biophys. Acta 1996, 1299, 125-140.
19. Morita, I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 2002, 68-69, 165-175.
20. Rigas, B.; Goldman, I. S.; Levine, L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 1993, 122, 518-523.
21. Rao, C. V.; Simi, B.; Wynn, T. T.; Garr, K.; Reddy, B. S. Modulating effect of amount and types of dietary fat on colonic mucosal phospholipase A2, phosphatidylinositol-specific phospholipase C activities, and cyclooxygenase metabolite formation during different stages of colon tumor promotion in male F344 rats. Cancer Res. 1996, 56, 532-537.
22. Eberhart, C. E.; Coffey, R. J.; Radhika, A.; Giardiello, F. M.; Ferrenbach, S.; DuBois, R. N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994, 107, 1183-1188.
23. Kutchera, W.; Jones, D. A.; Matsunami, N.; Groden, J.; McIntyre, T. M.; Zimmerman, G. A.; White, R. L.; Prescott, S. M. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc. Natl. Acad. Sci. USA 1996, 93, 4816-4820.
24. DuBois, R. N.; Radhika, A.; Reddy, B. S.; Entingh, A. J. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996, 110, 1259-1262.
25. Williams, C. S.; Luongo, C.; Radhika, A.; Zhang, T.; Lamps, L. W.; Nanney, L. B.; Beauchamp, R. D.; DuBois, R. N. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 1996, 111, 1134-1140.
26. Tsujii, M.; DuBois, R. N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995, 83, 493-501.
27. Tsujii, M.; Kawano, S.; Tsuji, S.; Sawaoka, H.; Hori, M.; DuBois, R. N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93, 705-716.
28. Vadlamudi, R.; Mandal, M.; Adam, L.; Steinbach, G.; Mendelsohn, J.; Kumar, R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999, 18, 305-314.
29. Murono, S.; Inoue, H.; Tanabe, T.; Joab, I.; Yoshizaki, T.; Furukawa, M.; Pagano, J. S. Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc. Natl. Acad. Sci. USA 2001, 98, 6905-6910.
30. Oshima, M.; Dinchuk, J. E.; Kargman, S. L.; Oshima, H.; Hancock, B.; Kwong, E.; Trzaskos, J. M.; Evans, J. F.; Taketo, M. M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87, 803-809.
31. Thun, M. J.; Henley, S. J.; Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 2002, 94, 252-266.
32. Rigau, J.; Piqué, J. M.; Rubio, E.; Planas, R.; Tarrech, J. M.; Bordas, J. M. Effects of long-term sulindac therapy on colonic polyposis. Ann. Intern. Med. 1991, 115, 952-954.
33. Steinbach, G.; Lynch, P. M.; Phillips, R. K.; Wallace, M. H.; Hawk, E.; Gordon, G. B.; Wakabayashi, N.; Saunders, B.; Shen, Y.; Fujimura, T.; Su, L. K.; Levin, B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000, 342, 1946-1952.
34. Oshima, M.; Murai, N.; Kargman, S.; Arguello, M.; Luk, P.; Kwong, E.; Taketo, M. M.; Evans, J. F. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 2001, 61, 1733-1740.
35. Milas, L.; Kishi, K.; Hunter, N.; Mason, K.; Masferrer, J. L.; Tofilon, P. J. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl. Cancer Inst. 1999, 91, 1501-1504.
36. Trifan, O. C.; Durham, W. F.; Salazar, V. S.; Horton, J.; Levine, B. D.; Zweifel, B. S.; Davis, T. W.; Masferrer, J. L. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res. 2002, 62, 5778-5784.
37. Ran, J. A.; Kim, J. I.; Ongusaha, P. P.; Hwang, D. H.; Ballou, L. R.; Mahale, A.; Aaronson, S. A.; Lee, S. W. P53-mediated induction of Cox-2 counteracts p53- or genotoxic stress-induced apoptosis. EMBO J. 2002, 21, 5635-5644.
38. Sheng, H.; Shao, J.; Kirkland, S. C.; Isakson, P.; Coffey, R. J.; Morrow, J.; Beauchamp, R. D.; Dubois, R. N. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J. Clin. Invest. 1997, 99, 2254-2259.
39. Kawamori, T.; Rao, C. V.; Seibert, K.; Reddy, B. S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998, 58, 409-412.
40. Elder, D. J.; Halton, D. E.; Hague, A.; Paraskeva, C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin. Cancer Res. 1997, 3, 1679-1683.
41. Piazza, G. A.; Rahm, A. K.; Finn, T. S.; Fryer, B. H.; Li, H.; Stoumen, A. L.; Pamukcu, R.; Ahnen, D. J. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 1997, 57, 2452-2459.
42. Bresalier, R. S.; Sandler, R. S.; Quan, H.; Bolognese, J. A.; Oxenius, B.; Horgan, K.; Lines, C.; Riddell, R.; Morton, D.; Lanas, A.; Constan, M. A.; Baron, J. A. N. Engl. J. Med. 2005, 352, 1092-1102.
43. Funk, C. D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001, 294, 1871-1875.
44. Romano, M.; Clària, J. Cyclooxygenase-2 and 5-Lipoxygenase converging functions on cell proliferation and tumor angiogenesis: Implications for cancer therapy. FASEB J. 2003, 17, 1986-1995.
45. Samuelsson, B.; Dahlen, S. E.; Lindgren, J. A.; Rouzer, C. A.; Serhan, C. N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987, 237, 1171-1176.
46. Funk, C. D.; Funk, L. B.; Fitzgerald, G. A.; Samuelsson, B. Characterization of human 12-lipoxygenase genes. Proc. Natl. Acad. Sci. USA 1992, 89, 3962-3966.
47. Borgeat, P.; Hamberg, M.; Samuelsson, B. Transformation of arachidonic acid and homo-gamma-linolenic acid by rabbit polymorphonuclear leukocytes. Monohydroxy acids from novel lipoxygenases. J. Biol. Chem. 1976, 251, 7816-7820.
48. Rouzer, C. A.; Matsumoto, T.; Samuelsson, B. Single protein from human leukocytes possesses 5-lipoxygenase and leukotriene A4 synthase activities. Proc. Natl. Acad. Sci. USA 1986, 83, 857-861.
49. 4 hydrolase in human leukocytes. Purification and properties. J. Biol. Chem. 1984, 259, 12339-12345.
50. 4 synthase. A pivotal enzyme in the biosynthesis of the cysteinyl leukotrienes. Am. J. Respir. Crit. Care Med 2000, 161, S16-19.
51. Radmark, O. Arachidonate 5-lipoxygenase. Prostaglandins Other Lipid Mediat. 2002, 68-69, 211-234.
52. Funk, C. D.; Hoshiko, S.; Matsumoto, T.; Radmark, O.; Samuelsson, B. Characterization of the human 5-lipoxygenase gene. Proc. Natl. Acad. Sci. USA 1989, 86, 2587-2591.
53. Hoshiko, S.; Radmark, O.; Samuelsson, B. Characterization of the human 5-lipoxygenase gene promoter. Proc. Natl. Acad. Sci. USA 1990, 87, 9073-9077.
54. Pouliot, M.; McDonald, P. P.; Krump, E.; Manzini, J. A.; McColl, S. R.; Weech, P. K.; Borgeat, P. Colocalization of cytosolic phospholipase A2, 5-lipoxygenase, and 5-lipoxygenase-activating protein at the nuclear membrane of A23187-stimulated human neutrophils. Eur. J. Biochem. 1996, 238, 250-258.
55. Dixon, R. A.; Diehl, R. E.; Opas, E.; Rands, E.; Vickers, P. J.; Evans, J. F.; Gillard, J. W.; Miller, D. K. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990, 343, 282-284.
56. 4 that mediates chemotaxis. Nature 1997, 387, 620-624.
57. Yokomizo, T.; Kato, K.; Terawaki, K.; Izumi, T.; Shimizu, T. A second leukotriene B(4) receptor, BLT2. A new therapeutic target in inflammation and immunological disorders. J. Exp. Med. 2000, 192, 421-432.
58. Lynch, K. R.; O'Neill, G. P.; Liu, Q.; Im, D. S.; Sawyer, N.; Metters, K. M.; Coulombe, N.; Abramovitz, M.; Figueroa D. J.; Zeng, Z.; Connolly, B. M.; Bai, C.; Austin, C. P.; Chateauneuf, A.; Stocco, R.; Greig, G. M.; Kargman, S.; Hooks, S. B.; Hosfield, E.; Williams, D. L. Jr.; Ford-Hutchinson, A. W.; Caskey, C. T.; Evans, J. F. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature 1999, 399, 789-793.
59. Heise, C. E.; O'Dowd, B. F.; Figueroa, D. J.; Sawyer, N.; Nguyen, T.; Im, D. S.; Stocco, R.; Bellefeuille, J. N.; Abramovitz, M.; Cheng, R.; Williams, D. L. Jr.; Zeng, Z.; Liu, Q.; Ma, L.; Clements, M. K.; Coulombe, N.; Liu, Y.; Austin, C. P.; George, S. R.; O'Neill, G. P.; Metters, K. M.; Lynch, K. R.; Evans, J. F. Characterization of the human cysteinyl leukotriene 2 receptor. J. Biol. Chem. 2000, 275, 30531-30536.
60. Powell, W. S.; Rokach, J. Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE. Prog. Lipid Res. 2005, 44, 154-183.
61. Hong, S. H.; Avis, I.; Vos, M. D.; Martinez, A.; Treston, A. M.; Mulshine, J. L. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors. Cancer Res. 1999, 59, 2223-2228.
62. Avis, I.; Hong, S. H.; Martinez, A.; Moody, T.; Choi, Y. H.; Trepel, J.; Das, R.; Jett, M.; Mulshine, J. L. Five-lipoxygenase inhibitors can mediate apoptosis in human breast cancer cell lines through complex eicosanoid interactions. FASEB J. 2001, 15, 2007-2009.
63. Avis, I. M.; Jett, M.; Boyle, T.; Vos, M. D.; Moody, T.; Treston, A. M.; Martinez, A.; Mulshine, J. L. Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling. J. Clin. Invest. 1996, 97, 806-813.
64. Kargman, S.; Vickers, P. J.; Evans, J. F. A23187 induces translocation of 5-lipoxygenase in osteosarcoma cells. J. Cell Biol. 1992, 119, 1701-1709.
65. Boado, R. J.; Pardridge, W. M.; Vinters, H. V.; Black, K. L. Differential expression of arachidonate 5-lipoxygenase transcripts in human brain tumors: evidence for the expression of a multitranscript family. Proc. Natl. Acad. Sci. USA 1992, 89, 9044-9048.
66. Hennig, R.; Ding, X. Z.; Tong, W. G.; Schneider, M. B.; Standop, J.; Friess, H.; Buchler, M. W.; Pour, P. M.; Adrian, T. E. 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am. J. Pathol. 2002, 161, 421-428.
67. Romano, M.; Catalano, A.; Nutini, M.; D'Urbano, E.; Crescenzi, C.; Clària, J.; Libner, R.; Davi, G.; Procopio, A. 5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor. FASEB J. 2001, 15, 2326-2336.
68. Gupta, S.; Srivastava, M.; Ahmad, N.; Sakamoto, K.; Bostwick, D. G.; Mukhtar, H. Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer 2001, 91, 737-743
69. 1, COX-2, and other cell survival factors in colorectal adenocarcinomas. Gastroenterology 2003, 124, 57-70.
70. Lee, E.; Robertson, T.; Smith, J.; Kilfeather, S. Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am. J. Respir. Crit. Care Med. 2000, 161, 1881-1886.
71. Walker, J. L.; Loscalzo, J.; Zhang, Y. Y. 5-Lipoxygenase and human pulmonary artery endothelial cell proliferation. Am. J. Physiol. 2002, 282, 585-593.
72. Uz, T.; Manev, R.; Manev, H. 5-Lipoxygenase is required for proliferation of immature cerebellar granule neurons in vitro. Eur. J. Pharmacol. 2001, 418, 15-22.
73. Ou, D.; Bonomi, P.; Jan, W.; Jadko, S.; Harris, J. E.; Anderson, K. M. The mode of cell death in H-358 lung cancer cells cultured with inhibitors of 5-hpoxygenase or the free radical spin trap, NTBN. Cancer Lett. 2001, 166, 223-231.
74. Ghosh, J.; Myers, C. E. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc. Natl. Acad. Sci. USA 1998, 95, 13182-13187.
75. Anderson, K. M.; Seed, T.; Meng, J.; Ou, D.; Alrefai, W. A., Harris, J. E. Five-lipoxygenase inhibitors reduce Panc-1 survival: the mode of cell death and synergism of MK886 with gamma linolenic acid. Anticancer Res. 1998, 18, 791-800.
76. Tsukada, T.; Nakashima, K.; Shirakawa, S. Arachidonate 5-lipoxygenase inhibitors show potent antiproliferative effects on human leukemia cell lines. Biochem. Biophys. Res. Commun. 1986, 140, 832-836.
77. Titos, E.; Clària, J.; Planagumà, A.; López-Parra, M.; Villamor, N.; Párrizas, M.; Carrió, A.; Miquel, R.; Jiménez, W.; Arroyo, V.; Rivera, F.; Rodés, J. Inhibition of 5-Lipoxygenase Induces Cell Growth Arrest and Apoptosis in Rat Kupffer Cells. Implications in liver fibrosis. FASEB J. 2003, 17, 1745-1747.
78. Catalano, A.; Caprari, P.; Soddu, S.; Procopio, A.; Romano, M. 5-Lipoxygenase antagonizes p53-induced apoptosis of cancer cells by altering p53 nuclear trafficking. FASEB J. 2004, 18, 1740-1742.
79. Baud, L.; Sraer, J.; Perez, J.; Nivez, M. P.; Ardaillou, R. Leukotriene C4 binds to human glomerular epithelial cells and promotes their proliferation in vitro. J. Clin. Invest. 1985, 76, 374-377.
80. Baud, L.; Perez, J.; Denis, M.; Ardaillou, R. Modulation of fibroblast proliferation by sulfidopeptide leukotrienes: effect of indomethacin. J. Immunol. 1987, 138, 1190-1195.
81. Yamaoka, K. A.; Claesson, H. E.; Rosen, A. Leukotriene B4 enhances activation, proliferation, and differentiation of human B lymphocytes. J. Immunol. 1989, 143, 1996-2000.
82. Leikauf, G. D.; Claesson, H. E.; Doupnik, C. A.; Hybbinette, A.; Grafstrom, R. C. Cysteinyl leukotrienes enhance growth of human airway epithelial cells. Am. J. Physiol. 1990, 259, L255-261.
83. Palmberg, L.; Lindgren, J. A.; Thyberg, J.; Claesson, H. E. On the mechanism of induction of DNA synthesis in cultured arterial smooth muscle cells by leukotrienes. Possible role of prostaglandin endoperoxide synthase products and platelet-derived growth factor. J. Cell Sci. 1991, 98, 141-149.
84. Kragballe, K.; Desjarlais, L.; Voohees, J. J. Leukotrienes B4, C4 and D4 stimulate DNA synthesis in cultured human epidermal keratinocytes. Br. J. Dermatol. 1985, 113, 43-52.
85. Moretti, R. M.; Montagnani Marelli, M.; Sala, A.; Motta, M.; Limonta, P. Activation of the orphan nuclear receptor RORalpha counteracts the proliferative effect of fatty acids on prostate cancer cells: crucial role of 5-lipoxygenase. Int. J. Cancer 2004, 112, 87-93.
86. Ghosh, J.; Myers, C. E. Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. Biochem. Biophys. Res. Commun. 1997, 235, 418-423.
87. Provost, P.; Samuelsson, B.; Radmark, O. Interaction of 5-lipoxygenase with cellular proteins. Proc. Natl. Acad, Sci. USA 1999, 96, 1881-1885.
88. Lepley, R. A.; Fitzpatrick, F. A. 5-Lipoxygenase contains a functional Src homology 3-binding motif that interacts with the Src homology 3 domain of Grb2 and cytoskeletal proteins. J. Biol. Chem. 1994, 269, 24163-24168.
89. Cao, Y.; Pearman, A. T.; Zimmerman, G. A.; McIntyre, T. M.; Prescott, S. M. Intracellular unesterified arachidonic acid signals apoptosis. Proc. Natl. Acad. Sci. USA 2000, 97, 11280-11285.
90. Tang, D. G.; Chen, Y. Q.; Honn, K. V. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc. Natl. Acad. Sci. USA 1996, 93, 5241-5246.
91. Datta, K.; Biswal, S. S.; Kehrer, J. P. The 5-lipoxygenase-activating protein (FLAP) inhibitor, MK886, induces apoptosis independently of FLAP. Biochem. J. 1999, 340, 371-375.
92. Yamamoto, S.; Suzuki, H.; Ueda, N. Arachidonate 12- lipoxygenases. Prog. Lipid Res. 1997, 36, 23-41.
93. Yoshimoto, T.; Takahashi, Y. Arachidonate 12-lipoxygenases. Prostaglandins Other Lipid Mediat. 2002, 68-69, 245-262.
94. Funk, C. D.; Furci, L.; Fitzgerald, G. A. Molecular cloning, primary structure, and expression of the human platelet/erythroleukemia cell 12-lipoxygenase. Proc. Natl. Acad. Sci. USA 1990, 87, 5638-5642.
95. Watanabe, T.; Medina, J. F.; Haeggstrom, J. Z.; Radmark, O.; Samuelsson, B. Molecular cloning of a 12-lipoxygenase cDNA from rat brain. Eur. J. Biochem. 1993, 212, 605-612.
96. De Marzo, N.; Sloane, D. L.; Dicharry, S.; Highland, E.; Sigal, E. Cloning and expression of an airway epithelial 12-lipoxygenase. Am. J. Physiol. 1992, 262, LI98-207.
97. Nie, D.; Honn, K. V. Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cell. Mol. Life Sci. 2002, 59, 799-807.
98. Nie, D.; Che, M.; Grignon, D.; Tang, K.; Honn, K. V. Role of eicosanoids in prostate cancer progression. Cancer Metastasis Rev. 2001, 20, 195-206.
99. Natarajan, R.; Esworthy, R.; Bai, W.; Gu, J. L.; Wilczynski, S.; Nadler, J. Increased 12-lipoxygenase expression in breast cancer tissues and cells. Regulation by epidermal growth factor. J. Clin. Endocrinol. Metab. 1997, 82, 1790-1798.
100. Krieg, P.; Kinzig, A.; Ress-Loschke, M.; Vogel, S.; Vanlandingham, B.; Stephan, M.; Lehmann, W. D.; Marks, F.; Furstenberger,G. 12-Lipoxygenase isoenzymes in mouse skin tumor development. Mol. Carcinog. 1995, 14, 118-129.
101. Chen, Y. Q.; Duniec, Z. M.; Liu, B.; Hagmann, W.; Gao, X.; Shimoji, K.; Marnett, L. J.; Johnson, C. R.; Honn, K. V. Endogenous 12(S)-HETE production by tumor cells and its role in metastasis. Cancer Res. 1994, 54, 1574-1579.
102. Steele, V. E.; Holmes, C. A.; Hawk, E. T.; Kopelovich, L.; Lubet, R. A.; Crowell, J. A.; Sigman, C. C.; Kelloff, G. J. Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomarkers Prev. 1999, 8, 467-483.
103. Liu, X. H.; Connolly, J. M.; Rose, D. P. The 12-lipoxygenase gene-transfected MCF-7 human breast cancer cell line exhibits estrogen-independent, but estrogen and omega-6 fatty acid-stimulated proliferation in vitro, and enhanced growth in athymic nude mice. Cancer Lett. 1996, 109, 223-230.
104. Brash, A. R. Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. J. Biol. Chem. 1999, 274, 23679-23682.
105. Brash, A. R.; Boeglin, W. E.; Chang, M. S. Discovery of a second 15S-lipoxygenase in humans. Proc. Natl. Acad. Sci. USA 1997, 94, 6148-6152.
106. Kelavkar, U. P.; Cohen, C.; Kamitani, H.; Eling, T. E.; Badr, K. F. Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging. Carcinogenesis 2000, 21, 1777-1787.
107. Shappell, S. B.; Boeglin, W. E.; Olson, S. J.; Kasper, S.; Brash, A. R. 15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma. Am. J. Pathol. 1999, 155, 235-245.
108. His, L. C.; Wilson, L. C.; Eling, T. E. Opposing Effects of 15-Lipoxygenase-1 and -2 Metabolites on MAPK Signaling in Prostate. Alteration in peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 2002, 277, 40549-40556.
109. Shappell, S. B.; Gupta, R. A.; Manning, S.; Whitehead, R.; Boeglin, W. E.; Schneider, C.; Case, T.; Price, J.; Jack, G. S.; Wheeler, T. M.; Matusik, R. J.; Brash, A. R.; DuBois, R. N. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. Cancer Res. 2001, 61, 497-503.
110. Argentieri, D. C.; Ritchie, D. M.; Ferro, M. P.; Kirchner, T.; Wachter, M. P.; Anderson, D. W.; Rosenthale, M. E.; Capetola, R. J. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. J. Pharmacol. Exp. Ther. 1994, 271, 1399-1408.
111. Fiorucci, S.; Meli, R.; Bucci, M.; Cirino, G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy? Biochem. Pharmacol. 2001, 62, 1433-1438.
112. Janusz, J. M.; Young, P. A.; Ridgeway, J. M.; Scherz, M. W.; Enzweiler, K; Wu, L. I.; Gan, L.; Darolia, R.; Matthews, R. S.; Hennes, D.; Kellstein, D. E.; Green, S. A.; Tulich, J. L.; Rosario-Jansen, T.; Magrisso, I. J.; Wehmeyer, K. R.; Kuhlenbeck, D. L.; Eichhold, T. H.; Dobson, R. L., Sirko, S. P.; Farmer, R. W. New cyclooxygenase-2/ 5-lipoxygenase inhibitors. 1. 7-tert-buty1-2,3-dihydro-3,3-dimethylbenzofuran derivatives as gastrointestinal safe antiinflammatory and analgesic agents: discovery and variation of the 5-keto substituent. J. Med Chem. 1998, 41, 1112-1123.
113. Inagaki, M.; Tsuri, T.; Jyoyama, H.; Ono, T.; Yamada, K.; Kobayashi, M.; Hori, Y.; Arimura, A.; Yasui, K.; Ohno, K.; Kakudo, S.; Koizumi, K.; Suzuki, R.; Kawai, S.; Kato, M.; Matsumoto, S. Novel antiarthritic agents with 1,2-isothiazolidine-1,1-dioxide (gamma-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase. J. Med. Chem. 2000, 43, 2040-2048.
114. Kirchner, T.; Argentieri, D. C.; Barbone, A. G.; Singer, M.; Steber, M.; Ansell, J.; Beers, S. A.; Watcher, M. P.; Wu, W.; Malloy, E.; Stewart, A.; Ritchie, D. M. Evaluation of the antiinflammatory activity of a dual cyclooxygenase-2 selective/5-lipoxygenase inhibitor, RWJ 63556, in a canine model of inflammation. J. Pharmacol. Exp. Ther. 1997, 282, 1094-1101.
115. Horizoe, T.; Nagakura, N.; Chiba, K.; Shirota, H.; Shinoda, M.; Kobayashi, N.; Numata, H.; Okamoto, Y.; Kobayashi, S. ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor with potent antiinflammatory activity in an arachidonic acid induced ear inflammation model. Inflamm. Res. 1998, 47, 375-383.
116. Horizoe, T.; Nagakura, N.; Chiba, K.; Shirota, H.; Shinoda, M.; Numata, H.; Kobayashi, S.; Abe, C. Effects of ER-34122, a novel dual 5-lipoxygenase/cyclooxygenase inhibitor, on indices of early articular lesion in MRL/MpJ-1pr/1pr mice. Inflamm. Res. 1999, 48, 432-436.
117. Tries, S.; Neupert, W.; Laufer, S. The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm. Res. 2002, 51, 135-143.
118. Laufer, S. A.; Augustin, J.; Dannhardt, G.; Kiefer, W. (6,7-Diaryldihydropyrrolizin-5-yl) acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase. J. Med. Chem. 1994, 37, 1894-1897.
119. Wallace, J. L.; Carter, L.; McKnight, W.; Tries, S.; Laufer, S. ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury. Eur. J. Pharmacol. 1994, 271, 525-531.
120. Bertolini, A.; Ottani, A.; Sandrini, M. Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol. Res. 2001, 44, 437-450.
121. Celotti, F.; Durand, T. The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy. Prostaglandins Other Lipid Mediat. 2003, 71, 147-162.
122. Charlier, C.; Michaux, C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. Eur. J. Med. Chem. 2003, 38, 645-659.
123. Boileau, C.; Pelletier, J. P.; Tardif, G.; Fahmi, H.; Laufer, S.; Lavigne, M.; Martel-Pelletier, J. The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway. Ann. Rheum. Dis. 2005, 64, 891-898.
124. Jovanovic, D. V.; Fernandes, J. C.; Martel-Pelletier, J.; Jolicoeur, F. C.; Reboul, P.; Laufer, S.; Tries, S.; Pelletier, J. P. In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1beta synthesis. Arthritis Rheum. 2001, 44, 2320-2330.
125. Chiang, N.; Arita, M.; Serhan, C. N. Anti-inflammatory circuitry: Lipoxin, aspirin-triggered lipoxins and their receptor ALX. Prostaglandins Leukot. Essent. Fatty Acids 2005, 73, 163-177.
126. Marcus, A. J. Transcellular metabolism of eicosanoids. Prog. Hemost. Thromb. 1986, 8, 127-142.
127. Serhan, C. N.; Sheppard, K. A. Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J. Clin. Invest. 1990, 85, 772-780.
128. Serhan, C. N.; Romano, M. Lipoxin biosynthesis and actions: role of the human platelet LX-synthase. J. Lipid. Mediat. Cell Signal. 1995, 12, 293-306.
129. Serhan, C. N.; Hamberg, M.; Samuelsson, B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc. Natl. Acad. Sci. USA 1984, 81, 5335-5339.
130. Clària, J.; Lee, M. H.; Serhan, C. N. Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)-neutrophil interactions and are potent inhibitors of cell proliferation. Mol. Med. 1996, 2, 583-596.
131. Levy, B. D.; Clish, C. B.; Schmidt, B.; Gronert, K.; Serhan, C. N. Lipid mediator class switching during acute inflammation: signals in resolution. Nat. Immunol. 2001, 2, 612-619.
132. Bannenberg, G. L.; Chiang, N.; Ariel, A.; Arita, M.; Tjonahen, E.; Gotlinger, K. H.; Hong, S.; Serhan, C. N. Molecular circuits of resolution: formation and actions of resolvins and protectins. J. Immunol. 2005, 174, 4345-4355.
133. Chavis, C.; Vachier, I.; Chanez, P.; Bousquet, J.; Godard, P. 5(S),15(S)-dihydroxyeicosatetraenoic acid and lipoxin generation in human polymorphonuclear cells: dual specificity of 5-lipoxygenase towards endogenous and exogenous precursors. J. Exp. Med. 1996, 183, 1633-1643.
134. Clària, J.; Titos, E.; Jiménez, W.; Ros, J.; Ginès, P.; Arroyo, V.; Rivera, F.; Rodés, J. Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with liver cirrhosis. Gastroenterology 1998, 115, 147-156.
135. Clària, J.; Serhan, C. N. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc. Natl. Acad. Sci. USA 1995, 92, 9475-9479.
136. Lee, T. H.; Horton, C. E.; Kyan-Aung, U.; Haskard, D.; Crea, A. E.; Spur, B. W. Lipoxin A4 and lipoxin B4 inhibit chemotactic responses of human neutrophils stimulated by leukotriene B4 and N-formyl-L-methiony1-L-leucyl-L-phenylanine. Clin. Sci. 1989, 77, 195-203.
137. Colgan, S. P.; Serhan, C. N.; Parkos, C. A.; Delp-Archer, C.; Madara, J. L. Lipoxin A4 modulates transmigration of human neutrophils across intestinal epithelial monolayers. J. Clin. Invest. 1993, 92, 75-82.
138. Papayianni, A.; Serhan, C. N.; Brady, H. R. Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. J. Immunol. 1996, 56, 2264-2272.
139. Gronert, K.; Gewirtz, A.; Madara, J. L.; Serhan, C. N. Identification of a human enterocyte lipoxin A4 receptor that is regulated by interleukin (IL)-13 and interferon gamma and inhibits tumor necrosis factor alpha-induced IL-8 release. J. Exp. Med. 1998, 187, 1285-1294.
140. Hachicha, M.; Pouliot, M.; Petasis, N. A.; Serhan, C. N. Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis. J. Exp. Med 1999, 189, 1923-1930.
141. 4. FASEB J. 2002, 16, 1937-1939.
142. Scalia, R.; Gefen, J.; Petasis, N. A.; Serhan, C. N.; Lefer, A. M. Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: role of P-selectin. Proc. Natl. Acad. Sci. USA 1997, 94, 9967-9972.
143. Takano, T.; Clish, C. B.; Gronert, K.; Petasis, N. A.; Serhan, C. N. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J. Clin. Invest. 1998, 101, 819-826.
144. Takano, T.; Fiore, S.; Maddox, J. F.; Brady, H. R.; Petasis, N. A.; Serhan, C. N. Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors. J. Exp. Med 1997, 185, 693-704.
145. Kieran, N. E.; Maderna, P.; Godson, C. Lipoxins: potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease. Kidney Int. 2004, 65, 1145-1154.
146. Pouliot, M.; Clish, C. B.; Petasis, N. A.; Van Dyke, T. E.; Serhan, C. N. Lipoxin A(4) analogues inhibit leukocyte recruitment to Porphyromonas gingivalis: a role for cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry 2000, 39, 4761-4768.
147. Van Dyke, T. E.; Serhan, C. N. Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J. Dent. Res. 2003, 82, 82-90.
148. Chiang, N.; Gronert, K.; Clish, C. B.; O'Brien, J. A.; Freeman, M. W.; Serhan, C. N. Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion. J. Clin. Invest. 1999, 104, 309-316.
149. Levy, B. D.; De Sanctis, G. T.; Devchand, P. R.; Kim, E.; Ackerman, K.; Schmidt, B. A.; Szczeklik W.; Drazen, J. M.; Serhan, C. N. Multi-pronged inhibition of airway hyperresponsiveness and inflammation by lipoxin A(4). Nature Med. 2002, 8, 1018-1023.
150. Karp, C. L.; Flick, L. M.; Park, K. W.; Softic, S.; Greer, T. M.; Keledjian, R.; Yang, R.; Uddin, J.; Guggino, W. B.; Atabani, S. F.; Belkaid, Y.; Xu, Y.; Whitsett, J. A.; Accurso, F. J.; Wills-Karp, M.; Petasis, N. A. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat. Immunol. 2004, 5, 388-392.
151. Fiorucci, S.; Wallace, J. L.; Mencarelli, A.; Distrutti, E.; Rizzo, G.; Farneti, S.; Morelli, A.; Tseng, J. L.; Suramanyam, B.; Guilford, W. J.; Parkinson, J. F. A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc. Natl. Acad. Sci. USA 2004, 101, 15736-15741.
152. Fierro, I. M.; Kutok, J. L.; Serhan, C. N. Novel lipid mediator regulators of endothelial cell proliferation and migration: aspirin-triggered-15R-lipoxin A(4) and lipoxin A(4). J. Pharmacol. Exp. Ther. 2002, 300, 385-392.
153. Fierro, I. M. Angiogenesis and lipoxins. Prostaglandins Leukot. Essent. Fatty Acids 2005, 73, 271-275.
154. McMahon, B.; Stenson, C.; McPhillips, F.; Fanning, A.; Brady, H. R.; Godson, C. Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors. J. Biol. Chem. 2000, 275, 27566-27575.
155. Mitchell, D.; Rodgers, K.; Hanly, J.; McMahon, B.; Brady, H. R.; Martin, F.; Godson, C. Lipoxins inhibit Akt/PKB activation and cell cycle progression in human mesangial cells. Am. J. Pathol. 2004, 164, 937-946.
156. McMahon, B.; Mitchell, D.; Shattock, R.; Martin, F.; Brady, H. R.; Godson, C. Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation. FASEB J. 2002, 16, 1817-1819.
157. Cezar-de-Mello, P. F.; Nascimiento-Silva, V.; Villela, C. G.; Fierro, I. M. Aspirin-triggered Lipoxin A(4) inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly. Oncogene 2005, 25, 122-129.
158. Wu, S. H.; Lu, C.; Dong, L.; Zhou, G. P.; He, Z. G.; Chen, Z. Q. High dose of lipoxin A4 induces apoptosis in rat renal interstitial fibroblasts. Prostaglandins Leukot. Essent. Fatty Acids 2005, 73, 127-137.
159. Jozsef, L.; Zouki, C.; Petasis, N. A.; Serhan, C. N.; Filep, J. G. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc. Natl. Acad. Sci. USA 2002, 99, 13266-13271.
160. Sodin-Semrl, S.; Tadeo, B.; Tseng, D.; Varga, J.; Fiore, S. Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J. Immunol. 2000, 164, 2660-2666.
161. Straus, D. S.; Glass, C. K. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med. Res. Rev. 2001, 21, 185-210.
162. Forman, B. M.; Tontonoz, P.; Chen, J.; Brun, R. P.; Speigelman, B. M.; Evans, R. M. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995, 83, 803-812.
163. Cernuda-Morollon, E.; Pineda-Molina, E.; Canada, F. J.; Perez-Sala, D. 15-Deoxy-Delta 12,14-prostaglandin J2 inhibition of NF-kappaB-DNA binding through covalent modification of the p50 subunit. J. Biol. Chem. 2001, 276, 35530-35536.
164. Thieringer, R.; Fenyk-Melody, J. E.; Le Grand, C. B.; Shelton, B. A.; Detmers, P. A.; Somers, E. P.; Carbin, L.; Moller, D. E.; Wright, S. D.; Berger, J. Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. J. Immunol. 2000, 164, 1046-1054.
165. Tsubouchi, Y.; Kawahito, Y.; Kohno, M.; Inoue, K.; Hla, T.; Sano, H. Feedback control of the arachidonate cascade in rheumatoid synoviocytes by 15-deoxy-Delta(12,14)-prostaglandin J2. Biochem. Biophys. Res. Commun. 2001, 283, 750-755.
166. Quraishi, O.; Mancini, J. A.; Riendeau, D. Inhibition of inducible prostaglandin E(2) synthase by 15-deoxy-Delta(12,14)-prostaglandin J(2) and polyunsaturated fatty acids. Biochem. Pharmacol. 2002, 63, 1183-1189.
167. Gilroy, D. W.; Lawrence, T.; Perretti, M.; Rossi, A. G. Inflammatory resolution: new opportunities for drug discovery Nat. Rev. Drug Discov. 2004, 3, 401-416.
168. Clay, C. E.; Namen, A. M.; Atsumi, G.; Willingham, M. C.; High, K. P.; Kute, T. E.; Trimboli, A. J.; Fonteh, A. N.; Dawson, P. A.; Chilton, F. H. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis 1999, 20, 1905-1911.
169. Wilmer, W. A.; Dixon, C.; Lu, L.; Hilbelink, T.; Rovin, B. H. A cyclopentenone prostaglandin activates mesangial MAP kinase independently of PPARgamma. Biochem. Biophys. Res. Commun. 2001, 281, 57-62.
170. Bishop-Bailey, D.; Hla, T. Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-Delta12, 14-prostaglandin J2. J. Biol. Chem. 1999, 274, 17042-17048.
171. 2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J. Clin. Invest. 2000, 106, 189-197.
172. Planagumà, A.; Clària, J.; Miquel, R.; López-Parra, M.; Titos, E.; Masferrer, J. L.; Arroyo, V.; Rodés, J. Inhibition of COX-2 reduces liver fibrosis by mechanisms involving kupffer cell apoptosis and PPARγ activation. FASEB J. 2005, 19, 1120-1122.
173. Gilroy, D. W.; Colville-Nash, P. R.; McMaster, S.; Sawatzky, D. A.; Willoughby, D. A.; Lawrence, T. Inducible cyclooxygenase-derived 15- deoxy(Delta)12-14PGJ2 brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis. FASEB J. 2003, 17, 2269-2271.
174. Ward, C.; Dransfield, I.; Murray, J.; Farrow, S. N.; Haslett, C.; Rossi, A. G. Prostaglandin D2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of I kappa B alpha degradation using a peroxisome proliferator-activated receptor-gamma-independent mechanism. J. Immunol. 2002, 168, 6232-6243.
175. Li, L.; Tao, J.; Davaille, J.; Feral, C.; Mallat, A.; Rieusset, J.; Vidal, H.; Lotersztajn, S. 15-deoxy-Delta 12,14-prostaglandin J2 induces apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome-proliferator-activated receptors. J. Biol. Chem. 2001, 276, 38152-38158.
176. Emi, M.; Maeyama, K. The biphasic effects of cyclopentenone prostaglandins, prostaglandin J(2) and 15-deoxy-Delta(12,14)-prostaglandin J(2) on proliferation and apoptosis in rat basophilic leukemia (RBL-2H3) cells. Biochem. Pharmacol. 2004, 67, 1259-1267.
177. Kondo, M.; Shibata, T.; Kumagai, T.; Osawa, T.; Shibata, N.; Kobayashi, M.; Sasaki, S.; Iwata, M.; Noguchi, N.; Uchida, K. 15-Deoxy-Delta(12,14)-prostaglandin J(2): the endogenous electrophile that induces neuronal apoptosis. Proc. Natl. Acad. Sci. USA 2002, 99, 7367-7372.
178. Castrillo, A.; Traves, P. G.; Martin-Sanz, P.; Parkinson, S.; Parker, P. J.; Bosca, L. Potentiation of protein kinase C zeta activity by 15-deoxy-delta(12,14)-prostaglandin J(2) induces an imbalance between mitogen-activated protein kinases and NF-kappa B that promotes apoptosis in macrophages. Mol. Cell. Biol. 2003, 23, 1196-1208.
179. Oliva, J. L.; Perez-Sala, D.; Castrillo, A.; Martinez, N.; Canada, F. J.; Bosca, L.; Rojas, J. M. The cyclopentenone 15-deoxy-delta 12,14-prostaglandin J2 binds to and activates H-Ras. Proc. Natl. Acad. Sci. USA 2003, 100, 4772-4777.
180. Millan, O.; Rico, D.; Painado, H.; Zarich, N.; Stamatakis, K.; Perez-Sala, D.; Rojas, J. M.; Cano, A.; Bosca, L. Potentiation of tumor formation by topical administration of 15-deoxy-deltal2,14-prostaglandin J2 in a model of skin carcinogenesis. Carcinogenesis 2006, 27, 328-336.